Empagliflozin effect on atrial fibrillation

Evaluation the effect of Empagliflozin on mitochondrial function in patients with paroxysmal atrial fibrillation

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20240623062224N1

Enrollment

110

Registered

2024-09-17

Start date

2024-07-14

Completion date

Unknown

Last updated

2025-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Paroxysmal atrial fibrillation. Paroxysmal atrial fibrillation

Interventions

Intervention 1: Intervention group: Empagliflozin 10 mg tablets manufactured by Actoverco company are taken orally for three months. Intervention 2: Control group: No drug is added.

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Having paroxysmal AF Being symptomatic during atrial fibrillation

Exclusion criteria

Exclusion criteria: Heart failure with ejection fraction = 50 percent Diabetes mellitus Chronic kidney disease (GFR<20ml/min) Liver cirrhosis History of urinary tract infection Pregnancy

Design outcomes

Primary

Measure	Time frame
Mitochondrial function. Timepoint: At the beginning of the study (before the intervention) and three months later. Method of measurement: Venous blood samples are taken from the patients and these biomarkers are measured: 1) total reactive oxygen species activity 2) total anti oxidant capacity 3) malondialdehyde concentration 4) 8 -hydroxy-2'-deoxy guanosine and 5) Mitochondrial DNA copy number in leukocytes.	—

Measure

Time frame

Mitochondrial function. Timepoint: At the beginning of the study (before the intervention) and three months later. Method of measurement: Venous blood samples are taken from the patients and these biomarkers are measured: 1) total reactive oxygen species activity 2) total anti oxidant capacity 3) malondialdehyde concentration 4) 8 -hydroxy-2'-deoxy guanosine and 5) Mitochondrial DNA copy number in leukocytes.

—

Secondary

Measure	Time frame
Quality of life. Timepoint: At the beginning of the study (before the start of the intervention) and three months later. Method of measurement: Atrial Fibrillation Effect on Quality of life (AFEQT) questionnaire.;Number of atrial fibrillation attacks. Timepoint: One, two and three months after starting the study. Method of measurement: Telephone interview.;Number of hospitalizations due to atrial fibrillation. Timepoint: One, two and three months after starting the study. Method of measurement: Telephone interview.;Left atrial function. Timepoint: At the beginning of the study (before the start of the intervention) and three months later. Method of measurement: Measurement of left atrial diameter, indexed volume and strain by transthoracic echocardiography.	—

Measure

Time frame

Quality of life. Timepoint: At the beginning of the study (before the start of the intervention) and three months later. Method of measurement: Atrial Fibrillation Effect on Quality of life (AFEQT) questionnaire.;Number of atrial fibrillation attacks. Timepoint: One, two and three months after starting the study. Method of measurement: Telephone interview.;Number of hospitalizations due to atrial fibrillation. Timepoint: One, two and three months after starting the study. Method of measurement: Telephone interview.;Left atrial function. Timepoint: At the beginning of the study (before the start of the intervention) and three months later. Method of measurement: Measurement of left atrial diameter, indexed volume and strain by transthoracic echocardiography.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAghil Zarbini Saydani

Tehran University of Medical Sciences

aghil.seydan@gmail.com+98 21 8802 9600

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026